Pathogenesis and Therapeutic Strategies Related to Non-Alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD), one of the most common types of chronic liver disease, is strongly correlated with obesity, insulin resistance, metabolic syndrome, and genetic components. The pathological progression of NAFLD, consisting of non-alcoholic fatty liver (NAFL), non-alcoholic...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-07-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/23/14/7841 |
| _version_ | 1797433444614012928 |
|---|---|
| author | Tieshan Teng Shuai Qiu Yiming Zhao Siyuan Zhao Dequan Sun Lingzhu Hou Yihang Li Ke Zhou Xixi Yu Changyong Yang Yanzhang Li |
| author_facet | Tieshan Teng Shuai Qiu Yiming Zhao Siyuan Zhao Dequan Sun Lingzhu Hou Yihang Li Ke Zhou Xixi Yu Changyong Yang Yanzhang Li |
| author_sort | Tieshan Teng |
| collection | DOAJ |
| description | Non-alcoholic fatty liver disease (NAFLD), one of the most common types of chronic liver disease, is strongly correlated with obesity, insulin resistance, metabolic syndrome, and genetic components. The pathological progression of NAFLD, consisting of non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH), and liver cirrhosis, is characterized by a broad spectrum of clinical phenotypes. Although patients with mild NAFL are considered to show no obvious clinical symptoms, patients with long-term NAFL may culminate in NASH and further liver fibrosis. Even though various drugs are able to improve NAFLD, there are no FDA-approved medications that directly treat NAFLD. In this paper, the pathogenesis of NAFLD, the potential therapeutic targets, and their underlying mechanisms of action were reviewed. |
| first_indexed | 2024-03-09T10:17:08Z |
| format | Article |
| id | doaj.art-305075eb7c824fe9b80ee1e779f42489 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-09T10:17:08Z |
| publishDate | 2022-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-305075eb7c824fe9b80ee1e779f424892023-12-01T22:15:44ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672022-07-012314784110.3390/ijms23147841Pathogenesis and Therapeutic Strategies Related to Non-Alcoholic Fatty Liver DiseaseTieshan Teng0Shuai Qiu1Yiming Zhao2Siyuan Zhao3Dequan Sun4Lingzhu Hou5Yihang Li6Ke Zhou7Xixi Yu8Changyong Yang9Yanzhang Li10Institute of Biomedical Informatics, School of Basic Medical Sciences, Henan University, Kaifeng 475004, ChinaInstitute of Biomedical Informatics, School of Basic Medical Sciences, Henan University, Kaifeng 475004, ChinaInstitute of Biomedical Informatics, School of Basic Medical Sciences, Henan University, Kaifeng 475004, ChinaInstitute of Biomedical Informatics, School of Basic Medical Sciences, Henan University, Kaifeng 475004, ChinaInstitute of Biomedical Informatics, School of Basic Medical Sciences, Henan University, Kaifeng 475004, ChinaInstitute of Biomedical Informatics, School of Basic Medical Sciences, Henan University, Kaifeng 475004, ChinaInstitute of Biomedical Informatics, School of Basic Medical Sciences, Henan University, Kaifeng 475004, ChinaInstitute of Biomedical Informatics, School of Basic Medical Sciences, Henan University, Kaifeng 475004, ChinaInstitute of Biomedical Informatics, School of Basic Medical Sciences, Henan University, Kaifeng 475004, ChinaInstitute of Biomedical Informatics, School of Basic Medical Sciences, Henan University, Kaifeng 475004, ChinaInstitute of Biomedical Informatics, School of Basic Medical Sciences, Henan University, Kaifeng 475004, ChinaNon-alcoholic fatty liver disease (NAFLD), one of the most common types of chronic liver disease, is strongly correlated with obesity, insulin resistance, metabolic syndrome, and genetic components. The pathological progression of NAFLD, consisting of non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH), and liver cirrhosis, is characterized by a broad spectrum of clinical phenotypes. Although patients with mild NAFL are considered to show no obvious clinical symptoms, patients with long-term NAFL may culminate in NASH and further liver fibrosis. Even though various drugs are able to improve NAFLD, there are no FDA-approved medications that directly treat NAFLD. In this paper, the pathogenesis of NAFLD, the potential therapeutic targets, and their underlying mechanisms of action were reviewed.https://www.mdpi.com/1422-0067/23/14/7841NAFLDsteatosisinflammationhepatic fibrosis |
| spellingShingle | Tieshan Teng Shuai Qiu Yiming Zhao Siyuan Zhao Dequan Sun Lingzhu Hou Yihang Li Ke Zhou Xixi Yu Changyong Yang Yanzhang Li Pathogenesis and Therapeutic Strategies Related to Non-Alcoholic Fatty Liver Disease International Journal of Molecular Sciences NAFLD steatosis inflammation hepatic fibrosis |
| title | Pathogenesis and Therapeutic Strategies Related to Non-Alcoholic Fatty Liver Disease |
| title_full | Pathogenesis and Therapeutic Strategies Related to Non-Alcoholic Fatty Liver Disease |
| title_fullStr | Pathogenesis and Therapeutic Strategies Related to Non-Alcoholic Fatty Liver Disease |
| title_full_unstemmed | Pathogenesis and Therapeutic Strategies Related to Non-Alcoholic Fatty Liver Disease |
| title_short | Pathogenesis and Therapeutic Strategies Related to Non-Alcoholic Fatty Liver Disease |
| title_sort | pathogenesis and therapeutic strategies related to non alcoholic fatty liver disease |
| topic | NAFLD steatosis inflammation hepatic fibrosis |
| url | https://www.mdpi.com/1422-0067/23/14/7841 |
| work_keys_str_mv | AT tieshanteng pathogenesisandtherapeuticstrategiesrelatedtononalcoholicfattyliverdisease AT shuaiqiu pathogenesisandtherapeuticstrategiesrelatedtononalcoholicfattyliverdisease AT yimingzhao pathogenesisandtherapeuticstrategiesrelatedtononalcoholicfattyliverdisease AT siyuanzhao pathogenesisandtherapeuticstrategiesrelatedtononalcoholicfattyliverdisease AT dequansun pathogenesisandtherapeuticstrategiesrelatedtononalcoholicfattyliverdisease AT lingzhuhou pathogenesisandtherapeuticstrategiesrelatedtononalcoholicfattyliverdisease AT yihangli pathogenesisandtherapeuticstrategiesrelatedtononalcoholicfattyliverdisease AT kezhou pathogenesisandtherapeuticstrategiesrelatedtononalcoholicfattyliverdisease AT xixiyu pathogenesisandtherapeuticstrategiesrelatedtononalcoholicfattyliverdisease AT changyongyang pathogenesisandtherapeuticstrategiesrelatedtononalcoholicfattyliverdisease AT yanzhangli pathogenesisandtherapeuticstrategiesrelatedtononalcoholicfattyliverdisease |